Multiple Different Strategies for Post-SELEX Optimization of Aptamers

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Multiple Different Strategies for Post-SELEX Optimization of Aptamers

Aptamers are oligonucleotides selected in vitro by SELEX (Systematic Evolution of Ligands by Exponential Enrichment) which can form a special three-dimensional structure and bind its target with high affinity and specificity. With many advantages over antibodies, such as stability and non-immunogenicity, aptamers show good prospects. However, just a few aptamers have entered clinical trials and only one, pegaptanib, has been approved by FDA for clinical use, because of their insufficient nuclease stability, thermal stability, bioavailability or even affinity. Aptamers need to be optimized to obtain better properties for application. This paper will highlight post-SELEX optimization of present aptamers in recent years. We will clarify four common strategies in detail including truncation, chemical modification, bivalent or multivalent aptamers construction and mutagenesis. A certain aptamer needs to be optimized to improve one or more specific properties according to different application purpose.


Citation: Zheng X, Hu B, Gao SX, Sun MJ, Wang LH (2015) Multiple Different Strategies for Post-SELEX Optimization of Aptamers. J Mol Biomark Diagn 6:224. doi: 10.4172/2155-9929.1000224

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger